Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 studyMuhammad A. Khattak, John M. Kirkwood, Piotr Rutkowski et al.|European Journal of Cancer|2022Cited by 22
Health-related quality of life (HRQoL) with pembrolizumab (pembro) in resected high-risk stage II melanoma in the phase 3 KEYNOTE-716 study.Muhammad Adnan Khattak, John M. Kirkwood, Jason J. Luke et al.|Journal of Clinical Oncology|2022Cited by 3